IVD Contract Research Organization Market ($8Bn by 2028) Growth Forecast at 7.8% CAGR During 2021 to 2028 COVID Impact and Global Analysis by The Insight Partners
March 30, 2022 13:52 ET
|
The Insight Partners
New York, March 30, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “IVD Contract Research Organization Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
March 24, 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to...
Veterinary Diagnostics Market Worth $9.58 billion by 2029 - Exclusive Report by Meticulous Research®
February 09, 2022 08:48 ET
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Feb. 09, 2022 (GLOBE NEWSWIRE) -- According to a new market research report “Veterinary Diagnostics Market by Product (Consumables {Leukemia, Influenza}, System, Software),...
Rapid Diagnostics Market Worth $18.20 Billion by 2029 — Exclusive Report by Meticulous Research®
February 01, 2022 07:00 ET
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Feb. 01, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled "Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers), Platform (Lateral...
Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
January 10, 2022 08:30 ET
|
Starton Therapeutics, Inc.
STAR-LLD is the first continuous delivery immunomodulatory drug (IMiD) in development to expand the use of lenalidomide in multiple myeloma and become the first IMiD for CLLOn track to complete...
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
December 13, 2021 16:30 ET
|
Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
December 13, 2021 16:05 ET
|
Adaptive Biotechnologies
Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patientsData in more than 30...
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
December 11, 2021 17:30 ET
|
Neoleukin Therapeutics, Inc.
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma...
Proteona announces multiple ASH presentations highlighting novel gene signatures in hematological cancers identified using advanced single-cell biomarker discovery platform
December 08, 2021 06:38 ET
|
Proteona
SINGAPORE, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Proteona, a single-cell precision medicine company, today announced that three abstracts from the company and its collaborators have been accepted for...
Aronora Announces Clinical Data to Be Presented at the 63rd American Society of Hematology Annual Meeting
December 06, 2021 08:00 ET
|
Aronora, Inc
PORTLAND, Ore., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing innovative therapies for hematologic diseases, today announced that clinical data...